Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platforms to potential new drug candidates is therefore very uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; (vi) if Nektar is unable to establish and maintain collaboration partnerships on attractive commercial terms (such as for NKTR-102), our business, results of operations and financial condition could suffer; and (vii) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the SEC on July 28, 2010, the Current Report on Form 8-K filed with the SEC today, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 to be filed with the SEC on or about November 4, 2010.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics(650) 631-4954Susan Noonan/SA Noonan Communications, LLC(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners(650) 575-1509 Michelle Corral/BCC Partners(415) 794-866
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... and AUSTIN, Texas , Oct. ... LLC today announced they have entered into a ... immunotherapies designed to target cancers. PhosImmune ... displayed on the surfaces of tumor cells in ... (PTTs), derived from proteins that play a role ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... Medical Hematology and Oncology CHU Lapeyronie, Montpellier ... that has long been recognized as a marker ... range of diagnostic markers to monitor infection and ... a necessity throughout the health care sector, it ...
... ,Since the first system was invented in 1957, ... patient care. During the 1960s, blood gas analysis ... considered "the most important laboratory test for critically ... Dr. John Severinghaus, inventor of the blood gas ...
Cached Medicine Technology:Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 2Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 3Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 4Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4
(Date:10/22/2014)... 2014 Best Cheap Hosting USA is ... The site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ... people from around the world. , “iPower is one ... and is providing various kinds of useful products for ... on offering excellent customer service and a number of ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... The Childrens Report of Sleep Patterns (CRSP), a ... and sleep disturbances for school-aged children, may be a ... hygiene, and sleep disturbances in children eight to 12 ... will be presented on Wednesday at SLEEP 2008, the ...
... Among the Top Healthcare IT Providers Underscores Cognizant,s ... in the Healthcare and Life Sciences Industry, ... leading provider of global consulting, technology and business,process ... ranked the 11th,largest healthcare IT provider by Healthcare ...
... For the first time, UCLA researchers have discovered that ... regions that help store memory. Reported in the June ... emphasize the importance of early detection of the disorder, ... , Sleep apnea occurs when a blocked airway ...
... Team of Physicians Give Manuel ... Uribe A New Lease on Life, DANVERS, Mass., June 10 ... man in the world, has,lost more than one-third of his body weight and ... by Dr. Barry Sears,creator of the Zone Diet. As he approaches his 43rd ...
... XL Capital Ltd,(NYSE: XL ) (the "Company") ... judgment handed down by the U.S. District Court for ... Lynch International. Merrill Lynch,International filed a complaint against Security ... Assurance Inc. (XLCA), relating to,certain credit default swap transactions ...
... effects of biomarkers most promising way,to help older ... 10 The Kronos Longevity,Research Institute (KLRI) has ... "the vicious triad" of the aging process: oxidative ... age-related,deteriorations and diseases. Longevity scientists across the country ...
Cached Medicine News:Health News:'Children's Report of Sleep Patterns' a reliable, maybe a valid measure of children's sleep habits 2Health News:Cognizant Ranks #11 on Healthcare Informatics 100 List 2Health News:Cognizant Ranks #11 on Healthcare Informatics 100 List 3Health News:Memory loss linked to common sleep disorder 2Health News:Memory loss linked to common sleep disorder 3Health News:Video: World's Heaviest Man Celebrates Birthday and Weight Loss Milestone 2Health News:Video: World's Heaviest Man Celebrates Birthday and Weight Loss Milestone 3Health News:XL Capital Ltd Issues Statement Regarding Merrill Lynch Lawsuit Against XL Capital Assurance Inc. (XLCA) a Subsidiary of Security Capital Assurance Ltd 2Health News:New KLRI Reports Shows Longevity Science Moving Beyond Studying the Obvious to the 'Downward Spiral' Paradigm in the Aging Process 2Health News:New KLRI Reports Shows Longevity Science Moving Beyond Studying the Obvious to the 'Downward Spiral' Paradigm in the Aging Process 3
... Dengue virus belongs to the Flavavirus group ... throughout the tropics.,Symptoms of Dengue fever are ... in the back and limbs, lymphadenopathy,maculopapular rash ... professional use as an aid in the ...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
For the rapid determination of human chorionic gonadotropin (hCG) in urine. The test strip is used to obtain a visual qualitative result....
Medicine Products: